M-PREDROL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for M-PREDROL (M-PREDROL).
Methylprednisolone is a glucocorticoid receptor agonist. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of pro-inflammatory cytokines, chemokines, and adhesion molecules. It also inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Hepatic metabolism primarily via CYP3A4 and CYP3A5 isoenzymes. Methylprednisolone is also metabolized via reduction and conjugation to inactive metabolites. |
| Excretion | Primarily hepatic metabolism; <20% excreted unchanged in urine. Negligible biliary/fecal elimination. |
| Half-life | Terminal elimination half-life: 2–4 hours. Clinical context: shorter than other corticosteroids; requires multiple daily doses for sustained anti-inflammatory effect. |
| Protein binding | Approximately 75% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Vd: 1–1.5 L/kg. Clinical meaning: distributes extensively into tissues; reflects high penetration into cells and sites of inflammation. |
| Bioavailability | Oral: 60–80%; Intramuscular: 70–100%; Intravenous: 100%. |
| Onset of Action | Intravenous: 5–15 minutes; Intramuscular: 1–2 hours; Oral: 2–4 hours. |
| Duration of Action | Duration: 48–72 hours for pituitary-adrenal suppression. Clinical notes: Single dose may suppress cortisol for 24–36 hours; tapering needed to avoid adrenal insufficiency. |
| Molecular Weight | 374.47 |
4 to 48 mg/day orally or intramuscularly in divided doses every 12 hours; for acute conditions, up to 120 mg/day intravenously in divided doses every 4-6 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, use 50% of normal dose. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: use 75% of normal dose; Child-Pugh C: use 50% of normal dose. |
| Pediatric use | 0.5-2 mg/kg/day orally or intramuscularly in divided doses every 6-12 hours; maximum 60 mg/day. |
| Geriatric use | Start at lowest effective adult dose; monitor for hyperglycemia, osteoporosis, and adrenal suppression. |
| 1st trimester | Corticosteroids may increase risk of cleft palate if used during first trimester. Use only if clearly indicated. |
| 2nd trimester | May be used for fetal maturation; consider risk-benefit. Chronic use may lead to fetal growth restriction. |
| 3rd trimester | Chronic use may cause neonatal adrenal suppression. Use for fetal lung maturity is indicated. |
Clinical note
Comprehensive clinical and safety monograph for M-PREDROL (M-PREDROL).
| Placental transfer | Methylprednisolone crosses the placenta; approximately 10-15% of maternal concentration reaches fetus. Predominantly metabolized to inactive form by placental 11-beta-hydroxysteroid dehydrogenase. |
| Breastfeeding | Methylprednisolone is excreted into breast milk in small amounts; doses up to 80 mg/day are considered compatible with breastfeeding. Monitor infant for potential adrenal suppression. |
■ FDA Black Box Warning
None.
| Serious Effects |
Systemic fungal infectionKnown hypersensitivity to methylprednisolone or any component
| Precautions | Adrenal suppression: Risk of secondary adrenocortical insufficiency upon withdrawal, especially after prolonged therapy., Immunosuppression and increased susceptibility to infections., Masking of signs of infection., Cushing's syndrome with chronic use., Osteoporosis, especially with long-term use., Gastrointestinal perforation or bleeding, particularly in patients with inflammatory bowel disease or diverticulitis., Exacerbation of pre-existing psychiatric conditions (e.g., euphoria, insomnia, mood swings)., Increased intraocular pressure, glaucoma, and cataracts., Fluid and electrolyte disturbances (e.g., hypertension, edema, hypokalemia)., Growth suppression in children., Thrombotic events (uncommon)., Kaposi's sarcoma has been reported in patients on corticosteroid therapy. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase drug levels; limit sodium intake to reduce fluid retention; increase potassium-rich foods (bananas, spinach) to counteract hypokalemia. |
Loading safety data…
| Lactation Rating | L2 |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (7-fold relative risk) and congenital heart defects with systemic doses >10 mg/day. Second/third trimester: Fetal growth restriction, adrenal suppression, oligohydramnios, and premature birth. Chronic use: Neonatal adrenal crisis. |
| Fetal Monitoring | Maternal: Blood pressure, glucose tolerance, bone density, eye exams, growth scans. Fetal: Ultrasound for growth restriction and amniotic fluid index every 4-6 weeks. Neonatal: Assess for adrenal insufficiency and infection. |
| Fertility Effects | May impair ovulation due to hormonal suppression at high doses. Reversible after discontinuation. No known effect on spermatogenesis. |
| Clinical Pearls | Methylprednisolone sodium succinate (M-PREDROL) is a high-potency corticosteroid for IV/IM use; taper dosing to avoid adrenal insufficiency; monitor for hyperglycemia, especially in diabetic patients; consider stress-dose steroids in perioperative setting if patient has been on chronic therapy. |
| Patient Advice | Do not stop taking this medication suddenly without consulting your doctor. · Report any signs of infection (fever, sore throat) or unusual weight gain. · May cause increased blood sugar; monitor glucose levels if diabetic. · Avoid live vaccines while on this medication. · Take with food or milk to reduce stomach upset. |